Abstract: A mounting arrangement for coupling to a device having a pair of sockets includes a mount having a base, a ball, and a neck coupling the ball to the base; two device engagement units, each of the device engagement units having a receiving platform and a leg extending from the receiving platform, each of the legs of the two device engagement units having a male socket engagement element to engage one of the sockets of the device; and two fasteners to fasten the mount to the two device engagement units. The mounting arrangement is configured for the base to be received by, and fastened to, both of the receiving platforms of the two device engagement units and for the base to form a wedge pushing the male socket engagement elements into engagement with the sockets of the device to non-rotatably secure the mounting arrangement to the device.

Abstract: A steerable vehicle suspension can include an axle, at least one retractor having a length that decreases in response to a pressure increase applied to the retractor, and at least one wheel spindle. Resistance to rotation of the wheel spindle relative to the axle increases in response to the pressure increase applied to the retractor. A method of operating a steerable vehicle suspension of a vehicle can include allowing steering knuckles rotatably mounted at opposite ends of an axle to rotate relative to the axle while the vehicle moves forward, and applying an inwardly directed force simultaneously to each of the steering knuckles. Another steerable vehicle suspension can include two rotatably mounted steering knuckles, and two retractors connected to the steering knuckles. An inwardly directed force is applied by each retractor to a respective one of the steering knuckles in response to pressure applied to the retractors.

Abstract: New poly(ethylene imine)-based copolymers for bonding to and releasing genetic material, in particular DNA/RNA, and method for the production and use of same. The copolymers according to a compound of the general Formula I: can be produced at low costs and with little expenditure of time, are tailor-made and have a high functionality for universal effective uses without restriction of their bonding affinity to genetic material.

Abstract: A vehicle suspension system can include a trunnion tube positioned between two axles, and at least one spring set attached to the axles and rotatably attached to the trunnion tube. An outer diameter of the trunnion tube can be substantially equal to an outer diameter of the axles. In another example, two of the trunnion stands can be positioned entirely between two of the spring sets and welded to the trunnion tube. In yet another example, a ratio of a distance between axle centers to an outer diameter of the trunnion tube can be less than 11 to 1. In a further example, the trunnion tube and the axles may be made of a same material. In a still further example, a ratio of the outer diameter of the trunnion tube to a wall thickness of a bushing on the trunnion tube can be greater than 9 to 1.

Abstract: A stopping-time calculation module for a vehicle contains a communication device, which enables communication with one or more other vehicles in order to transmit the vehicle's own travel-related data and/or to receive travel-related data of another vehicle or vehicles. An evaluation device is connected to the communication device and is suitable for calculating an extended stopping time that exceeds the stopping time specified by the schedule in the event of a delay for the current stop or a following stop, in particular the next stop, indicated by the travel-related data of a vehicle driving ahead or behind on a common route equipped with stops, and for producing a control signal that indicates the calculated stopping time.

Abstract: The invention relates to a pH-dependent controlled release pharmaceutical composition, comprising a core, and an opioid, wherein the core is coated at least by one coating layer, controlling the release of the pharmaceutical composition, wherein the coating layer comprises a polymer mixture of i) 40-95% by weight, based on dry weight of the polymer mixture, of at least one water insoluble essentially neutral vinyl polymer, and ii) 5-60% by weight, based on dry weight of the polymer mixture, of at least one anionic polymer or copolymer, which is insoluble in a buffered medium below pH 4.0 and soluble at least in the range from pH 7.0 to pH 8.0, characterized in that the coating layer further comprises 110 to 250% by weight of a non-porous inert lubricant, 1 to 35% by weight of a neutral cellulosic compound and 1 to 25% by weight of an emulsifier, each calculated on dry weight of the polymer mixture.

Abstract: The invention relates to a controlled release pharmaceutical composition, comprising a core, comprising a pharmaceutical active ingredient, whereby the core is coated by an ethanol resistance conferring coating layer which has the effect of conferring the release profile of the pharmaceutical active ingredient to be resistant against the influence of ethanol, whereby the ethanol resistance conferring coating layer comprises at least 70% by weight of a mixture of a polymeric portion a) and an excipients portion b), with the polymeric portion a) is consisting of a water insoluble essentially neutral vinyl polymer or vinyl copolymer and the excipients portion b) is consisting of the excipients b1) 100 to 250% by weight of a non-porous inert lubricant, b2) 1 to 35% by weight of a cellulosic compound, b3) 0.1 to 25% by weight of an emulsifier and additionally or alternatively to b3), b4) 0.

Abstract: The invention relates to an oral dosage form, comprising at least one biologically active agent, formulation auxiliary substances and magnetizable particles, wherein the dosage form has an at least two phase composition, wherein the phases can dissolve in the body after oral administration due to their formulation and the magnetizable particles are bound in formulation auxiliary substances and are present in a magnetized state, wherein the magnetized particles are present in at least two phases of the dosage form and generate magnetic fields, wherein these phases dissolve at different times in the body after oral administration, and wherein the magnetic field strength with respect to time, position and movement in the body is acquired using a detection system and can be evaluated using a computer-based evaluation system.

Abstract: A stopping-time calculation module for a vehicle contains a communication device, which enables communication with one or more other vehicles in order to transmit the vehicle's own travel-related data and/or to receive travel-related data of another vehicle or vehicles. An evaluation device is connected to the communication device and is suitable for calculating an extended stopping time that exceeds the stopping time specified by the schedule in the event of a delay for the current stop or a following stop, in particular the next stop, indicated by the travel-related data of a vehicle driving ahead or behind on a common route equipped with stops, and for producing a control signal that indicates the calculated stopping time.

Abstract: The invention relates to a pharmaceutical or nutraceutical formulation comprising a core, comprising an active pharmaceutical or nutraceutical ingredient, a penetration promoter and a bioavailability promoting agent, and a polymeric coating for the gastrointestinal targeted release of the active ingredient, characterized in that the bioavailability promoting agent is a pharmaceutically acceptable inhibitor of proteolytic enzymes, which increases the oral bioavailability of the active ingredient by a factor of at least five, compared to a corresponding formulation without the bioavailability promoting agent.

Abstract: Wind farm and method of controlling operation of a wind farm. The wind farm including a plurality of wind power plants, each equipped in a same manner with a pivoted rotor structure and a control device for controlling the operation of the individual wind power plants. The control device is structured and arranged to synchronize the rotary motions of the rotor structures of at least some of the plurality of wind power plants.

Abstract: The invention relates to an oral, multiparticulate form of administration, comprising pellets in the size ranging from 50 to 2500 $g(m)m which are substantially constituted of a) an inner matrix layer containing nanoparticles that contain a nucleic acid active ingredient and being embedded in a matrix of a polymer having a mucoadhesive effect, and b) an outer film coating, substantially consisting of an anionic polymer or copolymer that is optionally formulated with pharmaceutically conventional adjuvants, especially emollients.

Abstract: The invention relates to a pharmaceutical or nutraceutical formulation comprising a core, comprising an active pharmaceutical or nutraceutical ingredient, a penetration promoter and a bioavailability promoting agent, and a polymeric coating for the gastrointestinal targeted release of the active ingredient, characterized in that the bioavailability promoting agent is a pharmaceutically acceptable inhibitor of proteolytic enzymes, which increases the oral bioavailability of the active ingredient by a factor of at least five, compared to a corresponding formulation without the bioavailability promoting agent.

Abstract: The invention relates to an oral dosage form, comprising at least one biologically active agent, formulation auxiliary substances and magnetizable particles, wherein the dosage form has an at least two phase composition, wherein the phases can dissolve in the body after oral administration due to their formulation and the magnetizable particles are bound in formulation auxiliary substances and are present in a magnetized state, wherein the magnetized particles are present in at least two phases of the dosage form and generate magnetic fields, wherein these phases dissolve at different times in the body after oral administration, and wherein the magnetic field strength with respect to time, position and movement in the body is acquired using a detection system and can be evaluated using a computer-based evaluation system.

Abstract: Wind farm and method of controlling operation of a wind farm. The wind farm including a plurality of wind power plants, each equipped in a same manner with a pivoted rotor structure and a control device for controlling the operation of the individual wind power plants. The control device is structured and arranged to synchronize the rotary motions of the rotor structures of at least some of the plurality of wind power plants.

Abstract: The invention relates to a controlled release pharmaceutical composition, comprising a core, comprising a pharmaceutical active ingredient, whereby the core is coated by an ethanol resistance conferring coating layer which has the effect of conferring the release profile of the pharmaceutical active ingredient to be resistant against the influence of ethanol, whereby the ethanol resistance conferring coating layer comprises at least 70% by weight of a mixture of a polymeric portion a) and an excipients portion b), with the polymeric portion a) is consisting of a water insoluble essentially neutral vinyl polymer or vinyl copolymer and the excipients portion b) is consisting of the excipients b1) 100 to 250% by weight of a non-porous inert lubricant, b2) 1 to 35% by weight of a cellulosic compound, b3) 0.1 to 25% by weight of an emulsifier and additionally or alternatively to b3), b4) 0.

Abstract: The invention relates to a controlled release pharmaceutical composition, comprising a core, comprising a pharmaceutical active ingredient, whereby the core is coated by an ethanol resistance conferring coating layer which has the effect of conferring the release profile of the pharmaceutical active ingredient to be resistant against the influence of ethanol. The coating layer comprises a polymeric portion consisting of a water-insoluble neutral vinyl polymer or vinyl copolymer and an amino methacrylate copolymer and an excipients portion consisting of a lubricant, an emulsifier, a plasticizer and optionally a cellulosic compound.

Abstract: The invention relates to a pH-dependent controlled release pharmaceutical composition, comprising at least one pharmaceutical active ingredient, with the exception of opioids, wherein the core is coated at least by one coating layer, controlling the release of the pharmaceutical composition, wherein the coating layer comprises a polymer mixture of i) 40-95% by weight, based on dry weight of the polymer mixture, of at least one water insoluble essentially neutral vinyl polymer or copolymer, and ii) 5-60% by weight, based on dry weight of the polymer mixture, of at least one anionic polymer or copolymer, which is insoluble in a buffered medium below pH 4.0 and soluble at least in the range from pH 7.0 to pH 8.0, characterized in that the coating layer further comprises 110 to 250% by weight of a non-porous inert lubricant, 1 to 35% by weight of at least one neutral cellulosic compound and 1 to 25% by weight of at least one emulsifier, each calculated on dry weight of the polymer mixture.

Abstract: The invention relates to a pH-dependent controlled release pharmaceutical composition, comprising a core, and an opioid, wherein the core is coated at least by one coating layer, controlling the release of the pharmaceutical composition, wherein the coating layer comprises a polymer mixture of i) 40 95% by weight, based on dry weight of the polymer mixture, of at least one water insoluble essentially neutral vinyl polymer, and ii) 5 60% by weight, based on dry weight of the polymer mixture, of at least one anionic polymer or copolymer, which is insoluble in a buffered medium below pH 4.0 and soluble at least in the range from pH 7.0 to pH 8.0, characterized in that the coating layer further comprises 110 to 250 % by weight of a non-porous inert lubricant, 1 to 35 % by weight of a neutral cellulosic compound and 1 to 25 % by weight of an emulsifier, each calculated on dry weight of the polymer mixture.

Abstract: A diaper or other fluid arresting cover for a human body, bearing a weak base such as sodium bicarbonate for neutralizing acids in fluids secreted by the human body and intercepted by the fluid arresting cover. The fluid arresting cover may comprise in respective order a first water permeable wicking stratum, a second water permeable wicking stratum of different constituency than the first wicking stratum, a third stratum for absorbing water, a fourth stratum which is water permeable and can wick water to other strata, and a liquid impermeable outer membrane. The weak base may be incorporated into the third stratum or alternatively into the third and other strata. The weak base may be impregnated throughout a stratum or may comprise an exterior coating with adhesive engaging the exterior coating.